Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials

被引：41

作者：

Ibrahim, Nasrien E. ^{[1
]}

Gaggin, Hanna K. ^{[1
,2
]}

Konstam, Marvin A. ^{[3
]}

Januzzi, James L., Jr. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA

[2] Harvard Clin Res Inst, Boston, MA USA

[3] Tufts Med Ctr, Cardiovasc Ctr, Boston, MA USA

来源：

CIRCULATION-HEART FAILURE | 2016年 / 9卷 / 09期

关键词：

biomarkers; heart failure; natriuretic peptides; precision medicine; retrospective study; PRESERVED EJECTION FRACTION; BRAIN NATRIURETIC PEPTIDE; SURROGATE END-POINTS; ROSUVASTATIN MULTINATIONAL TRIAL; PROGNOSTIC VALUE; BLOCKER THERAPY; DOUBLE-BLIND; MORTALITY; NEPRILYSIN; INHIBITION;

D O I：

10.1161/CIRCHEARTFAILURE.115.002528

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The role of circulating biomarkers in heart failure clinical trials has evolved in recent decades. Increasing evidence behind the use of natriuretic peptides, emergence of novel biomarkers, and increased emphasis on targeting therapies toward physiological basis of disease (so-called precision medicine) have all contributed to the continued expansion of biomarker use in heart failure clinical trials. We will explore the advantages and pitfalls encountered through the use of biomarkers in clinical trials as an inclusion criterion, toxicity marker, and end point. We will also review their role in providing insights into the mechanism of action of therapeutics and guiding therapy in the management of patients with heart failure.

引用

页数：10

共 63 条

[1] Charting a Roadmap for Heart Failure Biomarker Studies [J].

Ahmad, Tariq ;

Fiuzat, Mona ;

Pencina, Michael J. ;

Geller, Nancy L. ;

Zannad, Faiez ;

Cleland, John G. F. ;

Snider, James V. ;

Blankenberg, Stephan ;

Adams, Kirkwood F. ;

Redberg, Rita F. ;

Kim, Jae B. ;

Mascette, Alice ;

Mentz, Robert J. ;

O'Connor, Christopher M. ;

Felker, G. Michael ;

Januzzi, James L. .

JACC-HEART FAILURE, 2014, 2 (05) :477-488

[2] Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction Findings From the I-PRESERVE Trial [J].

Anand, Inder S. ;

Rector, Thomas S. ;

Cleland, John G. ;

Kuskowski, Michael ;

McKelvie, Robert S. ;

Persson, Hans ;

McMurray, John J. ;

Zile, Michael R. ;

Komajda, Michel ;

Massie, Barry M. ;

Carson, Peter E. .

CIRCULATION-HEART FAILURE, 2011, 4 (05) :569-577

[3]

[Anonymous], J AM HEART ASS

[4] Biomarkers and surrogate endpoints [J].

Aronson, JK .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :491-494

[5] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study [J].

Bhardwaj, Anju ;

Rehman, Shafiq U. ;

Mohammed, Asim ;

Baggish, Aaron L. ;

Moore, Stephanie A. ;

Januzzi, James L., Jr. .

AMERICAN HEART JOURNAL, 2010, 159 (04) :532-U46

[6] Heart Failure [J].

Braunwald, Eugene .

JACC-HEART FAILURE, 2013, 1 (01) :1-20

[7]

Cao Thong Huy, 2015, Lancet, V385 Suppl 1, pS26, DOI 10.1016/S0140-6736(15)60341-5

[8] Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy -: The randomized evaluation of strategies for left ventricular dysfunction pilot study [J].

Cirillo, W ;

Decanini, R ;

Coelho, OR ;

Avezum, A ;

Peixoto, MSP ;

Piegas, LS ;

Neto, JMR ;

Paiva, M ;

Carvalho, AC ;

de Almeida, DR ;

Fernandes, IML ;

Malavasi, MC ;

Pavanello, R ;

Canesin, M ;

Ishii, S ;

Barretto, ACP ;

Imrie, J ;

Moore, R ;

Woo, K ;

Bernstein, V ;

Mizgala, HF ;

Mooney, S ;

Hilbich, D ;

Kuritzky, R ;

Rupka, DW ;

Blackwell, MM ;

Breakwell, L ;

Kornder, JM ;

Pearce, SA ;

Polasek, P ;

Richardson, PM ;

Grant, J ;

Isaac, D ;

Beresford, P ;

Giannoccaro, P ;

Roth, D ;

Greenwood, P ;

Muzyka, T ;

Prosser, A ;

Brass, N ;

Hui, W ;

Kvill, L ;

Goeres, M ;

MacDonald, K ;

Senaratne, M ;

Hill, L ;

Humen, D ;

Teo, KK ;

Habib, N ;

Habib, N .

CIRCULATION, 2000, 101 (04) :378-384

[9] The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial [J].

Cleland, John G. F. ;

Teerlink, John R. ;

Senior, Roxy ;

Nifontov, Evgeny M. ;

Mc Murray, John J. V. ;

Lang, Chim C. ;

Tsyrlin, Vitaly A. ;

Greenberg, Barry H. ;

Mayet, Jamil ;

Francis, Darrel P. ;

Shaburishvili, Tamaz ;

Monaghan, Mark ;

Saltzberg, Mitchell ;

Neyses, Ludwig ;

Wasserman, Scott M. ;

Lee, Jacqueline H. ;

Saikali, Khalil G. ;

Clarke, Cyril P. ;

Goldman, Jonathan H. ;

Wolff, Andrew A. ;

Malik, Fady I. .

LANCET, 2011, 378 (9792) :676-683

[10] Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) [J].

Cleland, John G. F. ;

McMurray, John J. V. ;

Kjekshus, John ;

Cornel, Jan H. ;

Dunselman, Peter ;

Fonseca, Candida ;

Hjalmarson, Ake ;

Korewicki, Jerzy ;

Lindberg, Magnus ;

Ranjith, Naresh ;

van Veldhuisen, Dirk J. ;

Waagstein, Finn ;

Wedel, Hans ;

Wikstrand, John .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (20) :1850-1859

← 1 2 3 4 5 6 7 →